Menassie Taddese
Fortuna: 148 412 $ al 30/09/2026
Fortuna: 148 412 $ al 30/09/2026
Mr. Menassie Taddese is an Independent Director at Medexus Pharmaceuticals, Inc. He is on the Board of Directors at Xeris Biopharma Holdings, Inc. and Medexus Pharmaceuticals, Inc. Mr. Taddese was previously employed as a President-Emerging Markets by Viatris, Inc.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 25/09/2025 | 42.869 ( 0,14 % ) | 148 412 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MEDEXUS PHARMACEUTICALS INC. | Director/Miembro de la Junta | 06/02/2023 |
| XERIS BIOPHARMA HOLDINGS, INC. | Director/Miembro de la Junta | 02/11/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| VIATRIS INC. | Corporate Officer/Principal | 01/12/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Virginia Polytechnic Institute & State University
Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medexus Pharmaceuticals, Inc.
Medexus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides healthcare products which focuses on therapeutic areas of auto-immune disease and pediatrics | Health Technology |
Viatris, Inc.
Viatris, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. BiotechnologyHealth Technology Develops and commercializes therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.